Total N = 1128 N (%) | Multimorbidity (CCI score ≥ 3) N = 105 N (%) | No multimorbidity (CCI score < 3) N = 1023 N (%) | p-value | |
---|---|---|---|---|
Age at the drug initiation, mean (SD) | 56.0 (12.1) | 65.1 (9.2) | 55.1 (12.0) | < 0.001 |
Disease duration, mean (SD) | 7.3 (7.8) | 10.3 (10.2) | 7.0 (7.4) | < 0.001 |
Sex (female) | 860 (76.2%) | 71 (67.6%) | 789 (77.1%) | 0.029 |
RF positive | 843/1099 (74.9%) | 77/99 (73.3%) | 766/999 (75.0%) | 0.250 |
ACPA positive | 244/1063 (21.7%) | 24/93 (22.9%) | 220/970 (21.6%) | 0.012 |
TJC | ||||
- Mean (SD) | 6.1 (5.7) | 6.2 (5.5) | 6.1 (5.8) | 0.948 |
- Median (IQR) | 5.0 [2.0–8.0] | 4.5 [2.0–8.5] | 5.0 [2.0–8.0] | 0.803 |
SJC | ||||
- mean (SD) | 4.2 (4.3) | 5.9 (5.2) | 4.0 (4.1) | < 0.001 |
- Median (IQR) | 3.0 [1.0–6.0] | 4.0 [2.0–8.0] | 3.0 [1.0–5.0] | < 0.001 |
PGH | ||||
- Mean (SD) | 5.8 (2.2) | 5.6 (2.2) | 5.9 (2.2) | 0.382 |
- Median (IQR) | 6.0 [5.0–7.0] | 6.0 [5.0–7.0] | 6.0 [5.0–7.0] | 0.401 |
ESR (mm/h) | ||||
- Mean (SD) | 28.9 (23.9) | 41.7 (29.9) | 27.6 (22.8) | < 0.001 |
- Median (IQR) | 22.0 [11.0–40.0] | 35.0 [17.0–59.0] | 21.5 [10.0–38.0] | < 0.001 |
CRP (mg/L) | ||||
- Mean (SD) | 7.6 (14.7) | 13.5 (20.4) | 7.1 (13.9) | < 0.001 |
- Median (IQR) | 2.5 [0.7–8.1] | 3.7 [1.3–20.2] | 2.4 [0.7–7.8] | 0.002 |
DAS28 | ||||
- Mean (SD) | 4.6 (1.3) | 5.0 (1.3) | 4.6 (1.3) | 0.002 |
- Median (IQR) | 4.6 [3.8–5.4] | 5.1 [4.2–5.9] | 4.6 [3.8–5.4] | |
Treatment | ||||
- TNF inhibitors | 693 (61.4%) | 40 (38.1%) | 653 (63.8%) | < 0.001 |
- IL6 inhibitors | 106 (9.4%) | 10 (9.5%) | 96 (9.4%) | |
- CD20 inhibitors | 55 (4.9%) | 12 (11.4%) | 43 (4.2%) | |
- JAK inhibitors | 166 (14.7%) | 19 (18.1%) | 147 (14.4%) | |
- CTLA4 inhibitors | 105 (9.3%) | 23 (21.9%) | 82 (8.0%) | |
- IL12/23 inhibitors | 2 (0.2%) | 1 (1.0%) | 1 (0.1%) | |
- IL1 inhibitors | 1 (0.1%) | 0 (0%) | 1 (0.1%) | |
Charlson Comorbidity index (mean), median [IQR] | 1.0 [1.0—1.0] | 3.0 [3.0—4.0] | 1.0 [1.0—1.0] | < 0.001 |